Study: "Profound" diagnoses of autism are far outnumbered by milder cases.

Published Date: 26 Apr 2023

Health officials have wondered how many U.S. children are being diagnosed with autism as it becomes more common. S. How many children experience more severe symptoms like a very low IQ and verbal immaturity, and how many kids have relatively mild symptoms?

Read Full News

Latest News

What’s All the Buzz? Trending Topics and Phrases of Neurology in 2025 Marco Meglio

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

Adults with Developmental and Epileptic Encephalopathies in the Precision Treatment Era Danielle Andrade, MD, MSc

Explore the evolving landscape of developmental and epileptic encephalopathies in adults, highlighting precision therapies and the need for accurate diagnoses.

Brain-Penetrant Molecule GT-02287 Demonstrates Reversal of Glucosylsphinogosine in Parkinson Disease Marco Meglio

Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.

Remyelinating Agent PIPE-307 Falls Short in Phase 2 Trial of Relapsing Multiple Sclerosis Marco Meglio

Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.

This Week on NeurologyLive® — December 22, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

CAPN2-Targeting Agent AMX0114 Shows Safe Profile in Phase 1 LUMINA Trial of ALS Marco Meglio

New findings from the LUMINA trial reveal AMX0114's safety in ALS patients, paving the way for further research and potential treatment advancements.

Todays Updates

NeurologyLive® Year in Review 2025: Notable Trials Beginning This Year NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.

NeuroVoices: Joseph Sullivan, MD, on ETX101 Gene Regulation Therapy and Early POLARIS Findings in Dravet Syndrome Marco Meglio

The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.

NeurologyLive® Year in Review 2025: Top Interviews in Multiple Sclerosis Care NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.

Hidradenitis Suppurativa in 2025: Year in Review

Hidradenitis Suppurativa in 2025: Year in Review

Todays Updates

NeurologyLive® Year in Review 2025: Notable Trials Beginning This Year NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.

NeuroVoices: Joseph Sullivan, MD, on ETX101 Gene Regulation Therapy and Early POLARIS Findings in Dravet Syndrome Marco Meglio

The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.

NeurologyLive® Year in Review 2025: Top Interviews in Multiple Sclerosis Care NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.

Hidradenitis Suppurativa in 2025: Year in Review

Hidradenitis Suppurativa in 2025: Year in Review

Latest News

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

Explore the evolving landscape of developmental and epileptic encephalopathies in adults, highlighting precision therapies and the need for accurate diagnoses.

Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.

Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.

Here's some of what is coming soon to NeurologyLive® this week.

New findings from the LUMINA trial reveal AMX0114's safety in ALS patients, paving the way for further research and potential treatment advancements.

News All Time

2024 Primary Stroke Prevention Guidelines: Key Takeaways and Clinical Implications Walter Kernan, MD, Isabella Ciccone, MPH

Walter Kernan, MD, senior research scientist at Yale University, discussed the latest primary stroke prevention guidelines and their focus on lifelong brain health and risk factor management.

Tolebrutinib Falls Short in Phase 3 PERSEUS Study, Forcing Decision to Redact Regulatory Submission Marco Meglio

Sanofi's tolebrutinib fails to meet key trial endpoints for multiple sclerosis, delaying FDA review and raising questions about its future in treatment.

Understanding the Therapeutic Potential and Promising Early-Stage Data on Azetukalner for Focal Onset Seizures Marco Meglio

Christopher Kenney, MD, FAAN, chief medical officer at Xenon Pharmaceuticals, reviews encouraging long-term data behind azetukalner, a first-in-class Kv7 channel opener, as a potential treatment for focal onset seizures.

How Social Robotics and Embodied AI Could Reshape Neurology Care Neal K. Shah

Neal K. Shah talked about how social robots could support emotional well-being in patients with neurologic conditions by reducing loneliness and promoting engagement in health-related activities.

NeurologyLive® Brain Games: December 14, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FcRn-blocking therapies in neurology!

This Week on NeurologyLive® — December 15, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Refining Prognosis and Treatment in Post–Resuscitation Epilepsy Care Andrea Rossetti, MD, Louie Pasculli

Andrea Rossetti, MD, director of the EEG/Epilepsy Unit at the Department of Clinical Neurosciences the Lausanne University Hospital in Switzerland, offers insight into post-resuscitation epilepsy care.

Beyond Dravet and LGS: Elizabeth Thiele, MD, PhD, on New Data for Epidiolex in DEEs Marco Meglio

Elizabeth Thiele, MD, PhD, director of the Pediatric Epilepsy Program at Massachusetts General Hospital, discusses new data on Epidiolex use in DEEs beyond Dravet, LGS, and TSC.

NeurologyLive® Friday 5 — December 12, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 12, 2025.

Investigational TRPM8 Antagonist Elismetrep Achieves Positive Phase 2b Data in Acute Migraine Isabella Ciccone, MPH

New data from a phase 2b trial showed that elismetrep showed favorable efficacy and safety outcomes compared with placebo, supporting its continued development as a potential acute migraine therapy.

Episode 156: Building Better Mood and Behavior Care for Parkinson Disease Marco Meglio, Sneha Mantri, MD, MS

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]

FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis Isabella Ciccone, MPH

Inebilizumab is the first CD19-targeted B-cell therapy approved for antiAChR- or antiMuSK antibody–positive generalized myasthenia gravis, providing symptom control with twice-yearly dosing.

FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS Isabella Ciccone, MPH

The phase 3 study aims to confirm findings from the HEALEY ALS platform trial in patients with early-stage rapidly progressive ALS, which suggested potential benefits of pridopidine across multiple domains.

EPX-100 Shows Promising Seizure Reduction in Ongoing Open-Label Extension Louie Pasculli

New data from the open-label extension of Harmony Biosciences’ Phase 3 ARGUS trial show that EPX-100 (clemizole) achieved a median 50% reduction in countable motor seizures in patients with Dravet Syndrome.

Cell Therapy Deramiocel Meets Primary End Point in Phase 3 DMD Cardiomyopathy Trial Isabella Ciccone, MPH

Capricor Therapeutics anticipates that detailed phase 3 data from the HOPE-3 study will be submitted for presentation at a future scientific meeting and for publication in a peer-reviewed journal.

Z-Rostudirsen Meets Primary End Point in Phase 1/2 DELIVER Trial for Duchenne Muscular Dystrophy Isabella Ciccone, MPH

Long-term treatment with z-rostudirsen over 24 months showed sustained functional improvements across all end points in patients with Duchenne muscular dystrophy amenable to exon 51 skipping.

Recommended News For You

Pickleball program boosts health and wellness for cancer survivors, study finds

Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.

enhancing survivors of brain tumors' quality of life.

novel approach to test the toxicity of cancer drugs.

Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer

Kate Middleton Announces Major Cancer Update

Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists

Recommended Articles For You

Bispecific Antibodies in DLBCL & Myeloma: Clinical Insights for Physicians 

Hope for a Cure: Exploring New Treatments for Sickle Cell Anemia 

Revolutionizing Thyroid Cancer: Advances in Molecular Genetics and Personalized Treatment Approaches 

Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Atezolizumab Consolidation Impresses in High-Risk DLBCL

2.

Breast cancer: Why it's difficult to treat and what new approaches are on the horizon

3.

Small Renal Mass Surveillance Does Not Affect Nephron-Sparing Surgery.

4.

Error on the MGUS-Autoimmune Disease Association.

5.

Veterans of the Navy have high lung cancer rates associated with asbestos use.

1.

Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec

2.

Unlocking the Power of Cryoprecipitate: A Comprehensive Guide

3.

The Importance of Balanced Potassium Levels in Maintaining Good Health

4.

Imaging in Peritoneal Neoplasms: Diagnostic Advances and Multimodal Treatment Strategies

5.

Optimizing the Diagnosis and Treatment of Hematological Diseases Through Artificial Intelligence

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials

2.

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion

3.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion

4.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion

5.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot